Navigation Links
Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
Date:6/12/2008

Study Showing Results of Tengion Neo-Bladder Augment(TM) to be Featured in

July Issue of the Journal of Urology

EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced today that the results of a preclinical research study conducted with its Neo-Bladder Augment(R) will be featured in the July issue of the Journal of Urology, Vol. 180. The paper, "Early Cellular and Stromal Responses in Regeneration Versus Repair of a Mammalian Bladder Using Autologous Cell and Biodegradable Scaffold Technologies," was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., Belinda J. Wagner, Ph.D. and Timothy A. Bertram, D.V.M., Ph.D.

Key findings of the preclinical trial -- in which either a Tengion Neo-Bladder Augment or a biodegradable mesh scaffold alone was surgically implanted following partial, trigone-sparing cystectomy and both groups were evaluated clinically at one, three, six and nine months -- show that the Tengion Neo-Bladder Augment restored baseline urodynamics as early as six months after implantation and led to a structurally and functionally complete regenerated bladder wall as early as nine months. In contrast, scaffold implants alone failed to return to urodynamic baseline by the study termination and failed to regenerate a complete bladder wall.

"We continue to see great promise in our neo-bladder research programs and these latest data underscore the potential of Tengion's Autologous Organ Regeneration Platform(TM) to provide a neo-organ that allows the body to regenerate a functional organ," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion. "We are looking forward to formally sharing these findings with our peers and continuing to develop our Neo-Bladder Augment and the Tengion Neo-Bladder Replacement(R) to meet the critical patient needs that exist today."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
6. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
7. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
8. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
9. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
10. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to a ... internet on Tuesday, March 14, 2017 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
(Date:2/24/2017)... Australie, le 24 février 2017 ITL Limited, ( ASX : ... innovante, est ravie d,annoncer les excellents résultats semestriels clos ... précédente correspondante. Une présentation complète « Résultats et mise à ... ici . Faits marquants ... (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care ... a top priority because it’s not if you will be attacked, but when.” However, ... it comes to digital health care. , Improvements in auditing and monitoring have taken ...
(Date:2/24/2017)... ... ... With ProGlass Prism users now have the ability to simulate prism distortions ... rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor point, ... users are given the tools and effects to generate a fractal prismatic displacement ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
Breaking Medicine News(10 mins):